Tools commonly used in the Cancer Research Centers industry for day-to-day tasks and operations.

• Flow cytometers
• Microscopes
• DNA sequencers
• Mass spectrometers
• Cell culture systems
• Animal models
• Gene editing tools (e.g. CRISPR/Cas9)
• High-throughput screening platforms
• Imaging software
• Tissue microarrays

Common products and services typical of NAICS Code 541715-21, illustrating the main business activities and contributions to the market.

• Cancer immunotherapy
• Precision medicine
• Cancer genomics
• Cancer stem cell research
• Cancer epidemiology
• Cancer prevention
• Radiation oncology
• Cancer pharmacology
• Cancer diagnostics
• Cancer clinical trials

The specific certifications, permits, licenses, and regulatory compliance requirements within the United States for this industry.

• Good Laboratory Practice (GLP): GLP is a quality system that ensures the safety and reliability of non-clinical laboratory studies. It is required by the FDA for studies submitted to support applications for research or marketing permits. The Organization for Economic Cooperation and Development (OECD) provides guidelines for GLP compliance.
• Institutional Animal Care and Use Committee (IACUC) Approval: IACUC approval is required for any research involving animals. The IACUC is responsible for ensuring that animal research is conducted in an ethical and humane manner. The National Institutes of Health (NIH) provides guidelines for IACUC approval.
• Institutional Review Board (IRB) Approval: IRB approval is required for any research involving human subjects. The IRB is responsible for ensuring that research is conducted in an ethical and safe manner. The Department of Health and Human Services (HHS) provides guidelines for IRB approval.
• Clinical Laboratory Improvement Amendments (CLIA) Certification: CLIA certification is required for any laboratory that performs testing on human specimens for the purpose of diagnosis, prevention, or treatment of disease. The Centers for Medicare & Medicaid Services (CMS) provides guidelines for CLIA certification.
• National Cancer Institute (NCI) Designation: NCI designation is awarded to cancer centers that meet certain criteria, including a focus on research and the ability to conduct clinical trials. NCI-designated cancer centers have access to funding and resources that are not available to non-designated centers.

A concise historical narrative of NAICS Code 541715-21 covering global milestones and recent developments within the United States.

• The history of the Cancer Research Centers industry dates back to the early 20th century when the first cancer research center, the American Society for the Control of Cancer (now known as the American Cancer Society), was established in 1913. In the following years, several other cancer research centers were established worldwide, including the Memorial Sloan Kettering Cancer Center in New York City in 1884, the National Cancer Institute in 1937, and the Dana-Farber Cancer Institute in 1947. These centers played a crucial role in advancing cancer research and developing new treatments. In recent history, the United States has seen significant progress in cancer research, including the development of immunotherapy, targeted therapy, and precision medicine. The Cancer Moonshot initiative launched in 2016 by former President Barack Obama aimed to accelerate cancer research and improve cancer prevention, diagnosis, and treatment. The initiative has led to several breakthroughs in cancer research, including the development of new immunotherapies and precision medicine treatments.

The anticipated future trajectory of the NAICS 541715-21 industry in the USA, offering insights into potential trends, innovations, and challenges expected to shape its landscape.

• Growth Prediction: Growing

  The future outlook for Cancer Research Centers in the USA is promising. With the advancements in technology and the increasing demand for cancer treatments, the industry is expected to grow in the coming years. The industry is expected to benefit from the increasing investment in cancer research and the development of new treatments. Additionally, the aging population in the USA is expected to increase the demand for cancer treatments, which will further drive the growth of the industry. However, the industry may face challenges such as the high cost of cancer treatments and the increasing competition from other countries. Overall, the Cancer Research Centers industry is expected to continue to grow in the USA in the coming years.

Recent groundbreaking advancements and milestones in the Cancer Research Centers industry, reflecting notable innovations that have reshaped its landscape.

• CAR-T Cell Therapy: A new type of cancer treatment that uses the patient's own immune cells to fight cancer.
• Liquid Biopsy: A non-invasive cancer diagnostic test that detects cancer cells in the blood.
• Immunotherapy: A type of cancer treatment that uses the patient's own immune system to fight cancer.
• Precision Medicine: A personalized approach to cancer treatment that takes into account the patient's genetic makeup and other factors.
• CRISPR Gene Editing: A new technology that allows scientists to edit genes and potentially cure genetic diseases.
• Nanoparticle Drug Delivery: A new method of drug delivery that uses nanoparticles to target cancer cells.
• 3D Printing: A new technology that allows scientists to create 3D models of cancer cells for research and drug development.
• Artificial Intelligence: A new tool that can help scientists analyze large amounts of data and develop new cancer treatments.
• Liquid Radiation Therapy: A new type of cancer treatment that uses liquid radiation to target cancer cells.
• Cancer Vaccines: A new type of cancer treatment that uses vaccines to stimulate the immune system to fight cancer.